CN102846624B - 一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 - Google Patents
一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN102846624B CN102846624B CN201210354977.4A CN201210354977A CN102846624B CN 102846624 B CN102846624 B CN 102846624B CN 201210354977 A CN201210354977 A CN 201210354977A CN 102846624 B CN102846624 B CN 102846624B
- Authority
- CN
- China
- Prior art keywords
- telmisartan
- hydrochlorothiazide
- recipe quantity
- pharmaceutical composition
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Compound telmisartan hydrochlorothiazide Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims abstract description 29
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960005187 telmisartan Drugs 0.000 claims abstract description 29
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 27
- OZCVMXDGSSXWFT-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OZCVMXDGSSXWFT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims description 33
- 239000011248 coating agent Substances 0.000 claims description 31
- 238000000576 coating method Methods 0.000 claims description 31
- 229930006000 Sucrose Natural products 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 15
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 15
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 238000007908 dry granulation Methods 0.000 claims description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000013270 controlled release Methods 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940101538 telmisartan 80 mg Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
替米沙坦 | 80mg |
氢氯噻嗪 | 12.5mg |
葡甲胺 | 12mg |
氢氧化钠 | 4mg |
微晶纤维素 | 200mg |
交联聚乙烯吡咯烷酮 | 20mg |
5%聚维酮K30水溶液 | 适量 |
硬脂酸镁 | 1.4mg |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210354977.4A CN102846624B (zh) | 2012-09-21 | 2012-09-21 | 一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210354977.4A CN102846624B (zh) | 2012-09-21 | 2012-09-21 | 一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102846624A CN102846624A (zh) | 2013-01-02 |
CN102846624B true CN102846624B (zh) | 2014-07-16 |
Family
ID=47393872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210354977.4A Expired - Fee Related CN102846624B (zh) | 2012-09-21 | 2012-09-21 | 一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102846624B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412180B (zh) * | 2017-06-17 | 2020-05-26 | 江西医学高等专科学校 | 一种帕利哌酮包芯片及其制备方法 |
CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢氯噻嗪片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2377521A1 (en) * | 2010-03-26 | 2011-10-19 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of telmisartan and diuretic combination |
-
2012
- 2012-09-21 CN CN201210354977.4A patent/CN102846624B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2377521A1 (en) * | 2010-03-26 | 2011-10-19 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of telmisartan and diuretic combination |
Also Published As
Publication number | Publication date |
---|---|
CN102846624A (zh) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101816637B (zh) | 来氟米特片制剂及其制备方法 | |
CN104055743B (zh) | 一种含利伐沙班口服制剂的制备方法 | |
CN102276516B (zh) | 一种苯磺酸左旋氨氯地平晶体、其制备方法及含有该晶体的药物组合物 | |
CN101695480A (zh) | 盐酸奥洛他定分散片及其制备方法和质量控制方法 | |
CN110393709B (zh) | 阿齐沙坦片及其制备方法 | |
CN103610677A (zh) | 一种瑞格列奈片剂及其制备方法 | |
CN102846624B (zh) | 一种复方替米沙坦氢氯噻嗪药物组合物及其制备方法 | |
CN105126111A (zh) | 提高索拉非尼生物利用度的制剂 | |
CN103462918A (zh) | 一种盐酸伐昔洛韦片剂及其制备方法 | |
GB2595141A (en) | Flupentixol melitracen tablet and preparation method therefor | |
CN109674754B (zh) | 一种氟哌噻吨美利曲辛药物组合物及其制剂 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
CN102302466A (zh) | 一种可粉末直接压片的卡培他滨药用组合物及其应用 | |
CN101947219B (zh) | 一种复方替米沙坦苯磺酸氨氯地平药物组合物及其制备方法 | |
CN102727447A (zh) | 一种氟苯尼考控释制剂及其制备方法 | |
CN106749174B (zh) | 一种西他沙星二水合物晶型、制备方法及其组合物片剂 | |
CN105232503A (zh) | 一种盐酸达泊西汀片 | |
CN104758266B (zh) | 一种非洛地平缓释片及其制备工艺 | |
CN103193700B (zh) | 一种苯磺酸左旋氨氯地平晶体及含有该晶体的药物组合物 | |
CN102860991A (zh) | 一种含非布司他的药物组合物及其制备方法 | |
CN102552920B (zh) | 一种含恩替卡韦的药物组合物及其制备方法 | |
CN102106805B (zh) | 赛米司酮固体制剂及其制备方法 | |
CN101721416B (zh) | 一种石杉碱甲固体组合物及其制备方法 | |
CN109985013B (zh) | 一种尼群地平分散片及其制备方法 | |
CN103479588B (zh) | 一种法莫替丁片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: PANG XIAOBIN Free format text: FORMER OWNER: TIANJIN SONGRUI MEDICAL TECHNOLOGY CO.,LTD. Effective date: 20140617 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Pang Xiaobin Inventor after: Xie Xinmei Inventor after: Guan Aimin Inventor after: Wang Baoquan Inventor after: Li Xiaoting Inventor before: Zhang Hao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300250 HEDONG, TIANJIN TO: 475000 KAIFENG, HENAN PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG HAO TO: PANG XIAOBIN XIE XINMEI GUAN AIMIN WANG BAOQUAN LI XIAOTING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140617 Address after: 475000, No. 1, building 101, Henan University, Jinming Road, Jinming District, Kaifeng City, Henan Applicant after: Pang Xiaobin Address before: 300250 Taixing apartment, Taixing Road, Hedong District, Tianjin, 14-1-102 Applicant before: Tianjin Songrui Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140716 Termination date: 20170921 |